Baillie Gifford Reduces Stake in Illumina

Institutional investor trims position in life sciences company

Apr. 13, 2026 at 7:26am

Got story updates? Submit your updates here. ›

A highly detailed, industrial-style close-up view of the intricate machinery and components inside a genetic sequencing laboratory, conveying the complex, high-tech nature of Illumina's business.An institutional investor's reduced stake in a leading genomics company reflects shifting market dynamics in the life sciences industry.San Diego Today

Baillie Gifford & Co., a major institutional investor, reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 3.6% in the fourth quarter, according to a recent disclosure with the Securities and Exchange Commission. The firm now owns approximately 1.06% of Illumina's outstanding shares.

Why it matters

Illumina is a leading provider of genetic sequencing technology, with its products used widely in academic research, clinical diagnostics, and the pharmaceutical industry. Changes in major institutional ownership can signal shifts in market sentiment and future growth prospects for the company.

The details

Baillie Gifford & Co. sold 59,916 shares of Illumina during the fourth quarter, reducing its total position to 1,626,776 shares. The firm remains one of Illumina's largest institutional shareholders, owning about 1.06% of the company's outstanding stock. Other large investors have also made changes to their Illumina holdings in recent quarters, with some increasing and others decreasing their positions.

  • Baillie Gifford reduced its Illumina stake in the fourth quarter of 2025.

The players

Baillie Gifford & Co.

A major global investment management firm that owns stakes in numerous public companies.

Illumina, Inc.

A leading life sciences company that develops and markets genetic sequencing technologies and products.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Baillie Gifford's Illumina position, while relatively small, could signal a shift in sentiment around the stock among some institutional investors. However, Illumina remains a core holding for many large funds, and its long-term growth prospects in the genomics industry continue to be viewed positively by analysts.